Several brokerages have updated their recommendations and price targets on shares of Ultragenyx Pharmaceutical (NASDAQ: RARE) in the last few weeks: 8/25/2016 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $86.00 price target on the stock. 8/9/2016 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by […]
